Dr. Bobak Parang Awarded Research Grant to Address Lung Cancer Drug Resistance
LUNGevity has awarded over $600,000 to Dr. Bobak Parang to research strategies for overcoming drug resistance in EGFR-positive non-small cell lung cancer.
Dr. Bobak Parang has been named the recipient of the Rising Tide/LUNGevity research award, securing more than $600,000 in funding to investigate drug resistance in EGFR-positive non-small cell lung cancer (NSCLC). The grant supports a clinical trial focused on identifying mechanisms to improve treatment outcomes for patients.
The project utilizes a combination of FDA-approved therapies to disrupt the pathways that cancer cells use to develop resistance. As many patients eventually see their tumors adapt to targeted therapies, the study seeks to mitigate this resistance and extend the efficacy of existing treatment options.
By leveraging established drugs, the research aims to address a critical gap in oncology care. The project is expected to provide clinical data on how secondary treatment strategies can improve survival rates for those with advanced NSCLC.